» Articles » PMID: 23500267

A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure

Overview
Date 2013 Mar 19
PMID 23500267
Citations 194
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study sought to compare catheter ablation with rate control for persistent atrial fibrillation (AF) in heart failure (HF).

Background: The optimal therapy for AF in HF is unclear. Drug-based rhythm control has not proved clinically beneficial. Catheter ablation improves cardiac function in patients with HF, but impact on physiological performance has not been formally evaluated in a randomized trial.

Methods: In a randomized, open-label, blinded-endpoint clinical trial, adults with symptomatic HF, radionuclide left ventricular ejection fraction (EF) ≤35%, and persistent AF were assigned to undergo catheter ablation or rate control. Primary outcome was 12-month change in peak oxygen consumption. Secondary endpoints were quality of life, B-type natriuretic peptide, 6-min walk distance, and EF. Results were analyzed by intention-to-treat.

Results: Fifty-two patients (age 63 ± 9 years, EF 24 ± 8%) were randomized, 26 each to ablation and rate control. At 12 months, 88% of ablation patients maintained sinus rhythm (single-procedure success 68%). Under rate control, rate criteria were achieved in 96%. The primary endpoint, peak oxygen consumption, significantly increased in the ablation arm compared with rate control (difference +3.07 ml/kg/min, 95% confidence interval: 0.56 to 5.59, p = 0.018). The change was not evident at 3 months (+0.79 ml/kg/min, 95% confidence interval: -1.01 to 2.60, p = 0.38). Ablation improved Minnesota score (p = 0.019) and B-type natriuretic peptide (p = 0.045) and showed nonsignificant trends toward improved 6-min walk distance (p = 0.095) and EF (p = 0.055).

Conclusions: This first randomized trial of ablation versus rate control to focus on objective exercise performance in AF and HF shows significant benefit from ablation, a strategy that also improves symptoms and neurohormonal status. The effects develop over 12 months, consistent with progressive amelioration of the HF syndrome. (A Randomised Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure; NCT00878384).

Citing Articles

Predictors of Improvement in Left Ventricular Systolic Dysfunction in Patients with Atrial Fibrillation Undergoing Catheter Ablation: Systematic Review.

Ahluwalia N, Hussain A, Providencia R, Schilling R Arrhythm Electrophysiol Rev. 2025; 14:e02.

PMID: 40017669 PMC: 11865674. DOI: 10.15420/aer.2024.24.


Catheter ablation in rate-controlled atrial fibrillation with severely reduced ejection fraction: intervention for irregularity-mediated cardiomyopathy.

Maidman S, Aizer A, Jankelson L, Holmes D, Park D, Bernstein S J Interv Card Electrophysiol. 2024; .

PMID: 39702550 DOI: 10.1007/s10840-024-01965-x.


Optimizing outcomes from cardiac resynchronization therapy: what do recent data and insights say?.

de Vere F, Wijesuriya N, Howell S, Elliott M, Mehta V, Mannakkara N Expert Rev Cardiovasc Ther. 2024; 1-18.

PMID: 39695920 PMC: 11716670. DOI: 10.1080/14779072.2024.2445246.


2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.

Tzeis S, Gerstenfeld E, Kalman J, Saad E, Sepehri Shamloo A, Andrade J J Arrhythm. 2024; 40(6):1217-1354.

PMID: 39669937 PMC: 11632303. DOI: 10.1002/joa3.13082.


Assessment of Redundant Meta-Analyses on Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure.

Shang L, Shao M, Zhu M, Li J, Gao M, Hou Y Rev Cardiovasc Med. 2024; 25(11):418.

PMID: 39618855 PMC: 11607499. DOI: 10.31083/j.rcm2511418.